Literature DB >> 17761916

Discontinuation of statin therapy and clinical outcome after ischemic stroke.

Furio Colivicchi1, Andrea Bassi, Massimo Santini, Carlo Caltagirone.   

Abstract

BACKGROUND AND
PURPOSE: The majority of patients with previous ischemic stroke are expected to benefit significantly from long-term statin therapy. However, discontinuation of medication therapy frequently occurs in clinical practice. The aim of this study was to assess the impact of discontinued statin therapy on clinical outcome in patients discharged after an acute ischemic stroke.
METHODS: The study population included 631 consecutive stroke survivors (322 men and 309 women; mean+/-SD age, 70.2+/-7.6 years) without clinical evidence of coronary heart disease. All patients were discharged on statin therapy and were followed up for 12 months after the acute ischemic stroke.
RESULTS: Within 12 months from discharge, 246 patients (38.9%) discontinued statin therapy; the mean time from discharge to statin discontinuation was 48.6+/-54.9 days (median time, 30 days; interquartile range, 18 to 55 days). During follow-up, 116 patients died (1-year probability of death=0.18; 95% CI, 0.15 to 0.21). Multivariate analysis demonstrated that after adjustment for all confounders and interactions, statin therapy discontinuation (hazard ratio=2.78; 95% CI, 1.96 to 3.72; P=0.003) was an independent predictor of all-cause 1-year mortality.
CONCLUSIONS: A large number of patients discontinue their use of statins early after acute stroke. Moreover, patients discontinuing statins have a significantly increased mortality during the first year after the acute cerebrovascular event. These findings suggest that patient care should be improved during the transition from a hospital setting to outpatient primary care.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17761916     DOI: 10.1161/STROKEAHA.107.487017

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  43 in total

Review 1.  Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review.

Authors:  Mary A De Vera; Vidula Bhole; Lindsay C Burns; Diane Lacaille
Journal:  Br J Clin Pharmacol       Date:  2014-10       Impact factor: 4.335

2.  Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.

Authors:  Ramon Lyu; Marinella Govoni; Qian Ding; Christopher M Black; Sumesh Kachroo; Tao Fan; Augstina Ogbonnaya; Prina Donga; Jerrold Hill; Charles Makin
Journal:  Rheumatol Int       Date:  2015-08-28       Impact factor: 2.631

3.  Recent trends in cost-related medication nonadherence among stroke survivors in the United States.

Authors:  Deborah A Levine; Lewis B Morgenstern; Kenneth M Langa; John D Piette; Mary A M Rogers; Sudeep J Karve
Journal:  Ann Neurol       Date:  2013-02-22       Impact factor: 10.422

4.  Family history of cardiovascular disease and influence on statin therapy persistence.

Authors:  Anna Citarella; Helle Kieler; Anders Sundström; Marie Linder; Björn Wettermark; Ingegärd Anveden Berglind; Morten Andersen
Journal:  Eur J Clin Pharmacol       Date:  2014-03-08       Impact factor: 2.953

5.  Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017.

Authors:  Makoto Kinoshita; Koutaro Yokote; Hidenori Arai; Mami Iida; Yasushi Ishigaki; Shun Ishibashi; Seiji Umemoto; Genshi Egusa; Hirotoshi Ohmura; Tomonori Okamura; Shinji Kihara; Shinji Koba; Isao Saito; Tetsuo Shoji; Hiroyuki Daida; Kazuhisa Tsukamoto; Juno Deguchi; Seitaro Dohi; Kazushige Dobashi; Hirotoshi Hamaguchi; Masumi Hara; Takafumi Hiro; Sadatoshi Biro; Yoshio Fujioka; Chizuko Maruyama; Yoshihiro Miyamoto; Yoshitaka Murakami; Masayuki Yokode; Hiroshi Yoshida; Hiromi Rakugi; Akihiko Wakatsuki; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2018-08-22       Impact factor: 4.928

6.  ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic-therapeutic pathway in Italy.

Authors:  Michele Massimo Gulizia; Furio Colivicchi; Gualtiero Ricciardi; Simona Giampaoli; Aldo Pietro Maggioni; Maurizio Averna; Maria Stella Graziani; Ferruccio Ceriotti; Alessandro Mugelli; Francesco Rossi; Gerardo Medea; Damiano Parretti; Maurizio Giuseppe Abrignani; Marcello Arca; Pasquale Perrone Filardi; Francesco Perticone; Alberico Catapano; Raffaele Griffo; Federico Nardi; Carmine Riccio; Andrea Di Lenarda; Marino Scherillo; Nicoletta Musacchio; Antonio Vittorio Panno; Giovanni Battista Zito; Mauro Campanini; Leonardo Bolognese; Pompilio Massimo Faggiano; Giuseppe Musumeci; Enrico Pusineri; Marcello Ciaccio; Enzo Bonora; Giorgio Cantelli Forti; Maria Pia Ruggieri; Claudio Cricelli; Francesco Romeo; Roberto Ferrari; Attilio Maseri
Journal:  Eur Heart J Suppl       Date:  2017-05-02       Impact factor: 1.803

Review 7.  The impact of statins on physical activity and exercise capacity: an overview of the evidence, mechanisms, and recommendations.

Authors:  Allyson M Schweitzer; Molly A Gingrich; Thomas J Hawke; Irena A Rebalka
Journal:  Eur J Appl Physiol       Date:  2020-04-04       Impact factor: 3.078

8.  Statins and clinical outcome of acute ischemic stroke: a systematic review.

Authors:  Shaheen E Lakhan; Sanjit Bagchi; Magdalena Hofer
Journal:  Int Arch Med       Date:  2010-09-29

9.  Impact of hyperlipidemia and statins on ischemic stroke outcomes after intra-arterial fibrinolysis and percutaneous mechanical embolectomy.

Authors:  Lucas Restrepo; Oh Young Bang; Bruce Ovbiagele; Latisha Ali; Doojin Kim; David S Liebeskind; Sidney Starkman; Fernando Vinuela; Gary R Duckwiler; Reza Jahan; Jeffrey L Saver
Journal:  Cerebrovasc Dis       Date:  2009-08-22       Impact factor: 2.762

Review 10.  The role of cholesterol and statins in stroke.

Authors:  Babak B Navi; Alan Z Segal
Journal:  Curr Cardiol Rep       Date:  2009-01       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.